The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

Episodic respiratory symptoms are especially common in children between ages 0 and 2 years and are not necessarily an indicator of childhood asthma. The greatest risk factor for progression from ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

As the prevalence of asthma continues to increase, the financial impact on the healthcare costs of the United States does as well. Managed care pharmacists are ideally situated to unite the shared ...

Please provide your email address to receive an email when new articles are posted on . Guidelines say patients with obesity and asthma should lose between 5% and 10% of their weight. Primary care ...